SCHEMBL18924506

SCHEMBL18924506

CCCCCc1cc(CC(C)(C)C)ccn1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LNPEP Q9UIQ6 1/20 0.44
KCNH2 Q12809 1/20 0.42
KDM4E B2RXH2 4/20 0.39
CYP3A4 P08684 3/20 0.39
LMNA P02545 2/20 0.39
TSHR P16473 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
ALDH1A1 P00352 2/20 0.36
HSD17B10 Q99714 2/20 0.36
MEN1 O00255 1/20 0.36
USP2 O75604 1/20 0.36
GAA P10253 1/20 0.36
MAPT P10636 1/20 0.36
HPGD P15428 1/20 0.36
RAB9A P51151 1/20 0.36
KMT2A Q03164 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
PDPK1 O15530 1/20 0.35
PTGS2 P35354 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18924478 0.87 KDM4E (0.50) KDM4ECYP3A4LMNATSHRL3MBTL1
SCHEMBL18924522 0.87 LNPEP (0.43) LNPEPKCNH2KDM4ECYP3A4LMNA
SCHEMBL1328611 0.85 LNPEP (0.48) LNPEPKCNH2KDM4ECYP3A4LMNA
SCHEMBL28244414 0.84 KCNH2 (0.50) LNPEPKCNH2KDM4ECYP3A4LMNA
SCHEMBL2553622 0.84 CYP3A4 (0.46) LNPEPKCNH2KDM4ECYP3A4LMNA
SCHEMBL29058198 0.84 KCNH2 (0.50) LNPEPKCNH2KDM4ECYP3A4LMNA
SCHEMBL27345656 0.84 KCNH2 (0.50) LNPEPKCNH2KDM4ECYP3A4LMNA
SCHEMBL2550616 0.84 NOS3 (0.50) LNPEPKCNH2KDM4ECYP3A4LMNA
SCHEMBL31280277 0.84 NOS3 (0.50) LNPEPKCNH2KDM4ECYP3A4LMNA
SCHEMBL2555694 0.82 KCNH2 (0.48) LNPEPKCNH2KDM4ECYP3A4LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11649222-B2 Compounds UNIVERSITETET I OSLO (NO) 2023-05-16 US disclosed
US-10961223-B2 Compounds UNIVERSITETET I OSLO (NO) 2021-03-30 US disclosed
US-20190284167-A1 COMPOUNDS UNIVERSITETET I OSLO (NO) 2019-09-19 US disclosed
US-9670172-B2 Heterocyclic compounds and methods of use MEDIVATION TECHNOLOGIES, INC. (US) 2017-06-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11649222-B2 Compounds SLC30A6, SLC39A11, SLC39A3 LNPEP 117/4885KCNH2 648/4885KDM4E 2941/4885
US-10961223-B2 Compounds SLC30A6, SLC39A11, SLC30A5 LNPEP 119/4885KCNH2 469/4885KDM4E 2847/4885
US-20190284167-A1 COMPOUNDS SLC30A6, SLC39A11, SLC30A5 LNPEP 119/4885KCNH2 469/4885KDM4E 2847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.